TWI554511B - New amyloid affinity compounds (8) - Google Patents
New amyloid affinity compounds (8) Download PDFInfo
- Publication number
- TWI554511B TWI554511B TW101119585A TW101119585A TWI554511B TW I554511 B TWI554511 B TW I554511B TW 101119585 A TW101119585 A TW 101119585A TW 101119585 A TW101119585 A TW 101119585A TW I554511 B TWI554511 B TW I554511B
- Authority
- TW
- Taiwan
- Prior art keywords
- pyridine
- imidazo
- iodo
- triazol
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 82
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 claims description 97
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 60
- 208000024827 Alzheimer disease Diseases 0.000 claims description 45
- 239000000126 substance Substances 0.000 claims description 27
- 230000002285 radioactive effect Effects 0.000 claims description 23
- 150000002367 halogens Chemical group 0.000 claims description 17
- 239000000032 diagnostic agent Substances 0.000 claims description 13
- 229940039227 diagnostic agent Drugs 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 12
- 238000003745 diagnosis Methods 0.000 claims description 10
- -1 pyridin-5-yl Imidazo[1,2-a]pyridine Chemical compound 0.000 claims description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000003636 chemical group Chemical group 0.000 claims description 2
- 125000003638 stannyl group Chemical group [H][Sn]([H])([H])* 0.000 claims description 2
- 125000005208 trialkylammonium group Chemical group 0.000 claims description 2
- SBXWFLISHPUINY-UHFFFAOYSA-N triphenyltin Chemical group C1=CC=CC=C1[Sn](C=1C=CC=CC=1)C1=CC=CC=C1 SBXWFLISHPUINY-UHFFFAOYSA-N 0.000 claims description 2
- AWOGYKQLZGNICG-UHFFFAOYSA-N 2-pyrrol-1-ylpyridine Chemical compound C1=CC=CN1C1=CC=CC=N1 AWOGYKQLZGNICG-UHFFFAOYSA-N 0.000 claims 2
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical group [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 claims 1
- 229940055764 triaz Drugs 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 117
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 86
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 81
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 66
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 43
- 238000006243 chemical reaction Methods 0.000 description 38
- 239000000203 mixture Substances 0.000 description 37
- 210000004556 brain Anatomy 0.000 description 36
- 239000002904 solvent Substances 0.000 description 35
- 239000000243 solution Substances 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 28
- 238000003786 synthesis reaction Methods 0.000 description 27
- 238000004809 thin layer chromatography Methods 0.000 description 27
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 20
- 239000007788 liquid Substances 0.000 description 20
- 238000000034 method Methods 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 238000005481 NMR spectroscopy Methods 0.000 description 17
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- 238000000926 separation method Methods 0.000 description 16
- 238000003384 imaging method Methods 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 229940125904 compound 1 Drugs 0.000 description 13
- 229940126214 compound 3 Drugs 0.000 description 13
- 239000013078 crystal Substances 0.000 description 13
- 229910052736 halogen Inorganic materials 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical compound C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 229940125898 compound 5 Drugs 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000003818 flash chromatography Methods 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 10
- 229940125782 compound 2 Drugs 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 239000002243 precursor Substances 0.000 description 10
- 239000012488 sample solution Substances 0.000 description 10
- 239000011630 iodine Substances 0.000 description 9
- 229910052740 iodine Inorganic materials 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 238000000376 autoradiography Methods 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- FVAUCKIRQBBSSJ-VVUPZWBASA-M sodium;iodine-123(1-) Chemical compound [Na+].[123I-] FVAUCKIRQBBSSJ-VVUPZWBASA-M 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000004884 grey matter Anatomy 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- IVILGUFRMDBUEQ-UHFFFAOYSA-N 5-iodopyridin-2-amine Chemical compound NC1=CC=C(I)C=N1 IVILGUFRMDBUEQ-UHFFFAOYSA-N 0.000 description 6
- FZWUJZDUBMASHV-UHFFFAOYSA-N C(C)C=1C=C2C=CC(C2=CC1)C=1C(=NC=CC1)Br Chemical compound C(C)C=1C=C2C=CC(C2=CC1)C=1C(=NC=CC1)Br FZWUJZDUBMASHV-UHFFFAOYSA-N 0.000 description 6
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 6
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 229960004132 diethyl ether Drugs 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000003941 amyloidogenesis Effects 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 229940087646 methanolamine Drugs 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000004885 white matter Anatomy 0.000 description 5
- 208000037259 Amyloid Plaque Diseases 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 206010002022 amyloidosis Diseases 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 238000002600 positron emission tomography Methods 0.000 description 4
- 238000001308 synthesis method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 4
- VSKHHCXZYMSCAQ-UHFFFAOYSA-N tributyl-[2-(6-pyrazol-1-ylpyridin-3-yl)imidazo[1,2-a]pyridin-6-yl]stannane Chemical compound C=1N2C=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=1C(C=N1)=CC=C1N1C=CC=N1 VSKHHCXZYMSCAQ-UHFFFAOYSA-N 0.000 description 4
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 3
- KSSFCLOOFDPYDJ-UHFFFAOYSA-N 2-(6-imidazol-1-ylpyridin-3-yl)-6-iodoimidazo[1,2-a]pyridine Chemical compound C=1N2C=C(I)C=CC2=NC=1C(C=N1)=CC=C1N1C=CN=C1 KSSFCLOOFDPYDJ-UHFFFAOYSA-N 0.000 description 3
- IAVCEBMLYVGBLA-UHFFFAOYSA-N 2-[1-[6-[2-fluoroethyl(methyl)amino]naphthalen-2-yl]ethylidene]propanedinitrile Chemical compound C1=C(C(C)=C(C#N)C#N)C=CC2=CC(N(CCF)C)=CC=C21 IAVCEBMLYVGBLA-UHFFFAOYSA-N 0.000 description 3
- ZWIARAQZLULYPG-NSCUHMNNSA-N 4-[(e)-2-[4-(methylamino)phenyl]ethenyl]phenol Chemical compound C1=CC(NC)=CC=C1\C=C\C1=CC=C(O)C=C1 ZWIARAQZLULYPG-NSCUHMNNSA-N 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 238000009206 nuclear medicine Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- MUKKGHQBUKOMTD-UHFFFAOYSA-N 1-(6-bromopyridin-3-yl)ethanone Chemical compound CC(=O)C1=CC=C(Br)N=C1 MUKKGHQBUKOMTD-UHFFFAOYSA-N 0.000 description 2
- 150000000215 1-octanols Chemical class 0.000 description 2
- ZQAQXZBSGZUUNL-UHFFFAOYSA-N 2-[4-(methylamino)phenyl]-1,3-benzothiazol-6-ol Chemical compound C1=CC(NC)=CC=C1C1=NC2=CC=C(O)C=C2S1 ZQAQXZBSGZUUNL-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- KPMVHELZNRNSMN-UHFFFAOYSA-N chembl1985849 Chemical compound N1=CC=C2NCCN21 KPMVHELZNRNSMN-UHFFFAOYSA-N 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 102000034240 fibrous proteins Human genes 0.000 description 2
- 108091005899 fibrous proteins Proteins 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- ONPRBQYAYYZYFC-UHFFFAOYSA-N tributyl-[2-(6-imidazol-1-ylpyridin-3-yl)imidazo[1,2-a]pyridin-6-yl]stannane Chemical compound C=1N2C=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=1C(C=N1)=CC=C1N1C=CN=C1 ONPRBQYAYYZYFC-UHFFFAOYSA-N 0.000 description 2
- OEKBNMATJYLCTO-UHFFFAOYSA-N 1-(6-pyrazol-1-ylpyridin-3-yl)ethanone Chemical compound N1=CC(C(=O)C)=CC=C1N1N=CC=C1 OEKBNMATJYLCTO-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- FHCUXGCMUASJQQ-UHFFFAOYSA-N 2-[(2-chlorophenyl)methylsulfanyl]-5-propyl-1,3,4-oxadiazole Chemical compound O1C(CCC)=NN=C1SCC1=CC=CC=C1Cl FHCUXGCMUASJQQ-UHFFFAOYSA-N 0.000 description 1
- ZQAQXZBSGZUUNL-BJUDXGSMSA-N 2-[4-(methylamino)phenyl]-1,3-benzothiazol-6-ol Chemical compound C1=CC(N[11CH3])=CC=C1C1=NC2=CC=C(O)C=C2S1 ZQAQXZBSGZUUNL-BJUDXGSMSA-N 0.000 description 1
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 1
- FDRCIXUKBBBOPH-UHFFFAOYSA-N 2-ethenyl-1,3-benzoxazole Chemical class C1=CC=C2OC(C=C)=NC2=C1 FDRCIXUKBBBOPH-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- FFRGARBVHOZLLG-UHFFFAOYSA-N 3-bromo-2,2-dimethyldecane Chemical compound CCCCCCCC(Br)C(C)(C)C FFRGARBVHOZLLG-UHFFFAOYSA-N 0.000 description 1
- KJDSORYAHBAGPP-UHFFFAOYSA-N 4-(3,4-diaminophenyl)benzene-1,2-diamine;hydron;tetrachloride Chemical compound Cl.Cl.Cl.Cl.C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 KJDSORYAHBAGPP-UHFFFAOYSA-N 0.000 description 1
- FGQRNGPGBIJMET-UHFFFAOYSA-N 4-(6-iodo-1,3-benzothiazol-2-yl)-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=CC=C(I)C=C2S1 FGQRNGPGBIJMET-UHFFFAOYSA-N 0.000 description 1
- ZDGRIJNRIGFCGI-UHFFFAOYSA-N 4-(6-iodo-1,3-benzoxazol-2-yl)-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=CC=C(I)C=C2O1 ZDGRIJNRIGFCGI-UHFFFAOYSA-N 0.000 description 1
- GUJHUHNUHJMRII-UHFFFAOYSA-N 4-(6-iodo-2-imidazo[1,2-a]pyridinyl)-N,N-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CN(C=C(I)C=C2)C2=N1 GUJHUHNUHJMRII-UHFFFAOYSA-N 0.000 description 1
- GSZMUPHKOPBPPS-GQCTYLIASA-N 5-[(e)-2-[6-(2-fluoroethoxy)-1,3-benzoxazol-2-yl]ethenyl]-n,n-dimethyl-1,3-thiazol-2-amine Chemical compound S1C(N(C)C)=NC=C1\C=C\C1=NC2=CC=C(OCCF)C=C2O1 GSZMUPHKOPBPPS-GQCTYLIASA-N 0.000 description 1
- UGSBCCAHDVCHGI-UHFFFAOYSA-N 5-nitropyridin-2-amine Chemical compound NC1=CC=C([N+]([O-])=O)C=N1 UGSBCCAHDVCHGI-UHFFFAOYSA-N 0.000 description 1
- OCTOILLJHDVLDG-UHFFFAOYSA-N 6-iodo-2-(6-pyrazol-1-ylpyridin-3-yl)imidazo[1,2-a]pyridine Chemical compound C=1N2C=C(I)C=CC2=NC=1C(C=N1)=CC=C1N1C=CC=N1 OCTOILLJHDVLDG-UHFFFAOYSA-N 0.000 description 1
- MNDDOZHAEAWPKC-UHFFFAOYSA-N 6-iodo-2-[6-(triazol-2-yl)pyridin-3-yl]imidazo[1,2-a]pyridine Chemical compound C=1N2C=C(I)C=CC2=NC=1C(C=N1)=CC=C1N1N=CC=N1 MNDDOZHAEAWPKC-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- CNTSPTKKUNYKDY-UHFFFAOYSA-N C(C)(=O)C=1C=CC(=NC1)Br.C(C)(=O)C=1C=CC(=NC1)Br Chemical compound C(C)(=O)C=1C=CC(=NC1)Br.C(C)(=O)C=1C=CC(=NC1)Br CNTSPTKKUNYKDY-UHFFFAOYSA-N 0.000 description 1
- STKSXKCGUDTAAA-UHFFFAOYSA-N C(C)(=O)C=1C=CC(=NC1)N1C=NC=C1.C(C)(=O)NC=1C=CC(=NC1)N1C=NC=C1 Chemical compound C(C)(=O)C=1C=CC(=NC1)N1C=NC=C1.C(C)(=O)NC=1C=CC(=NC1)N1C=NC=C1 STKSXKCGUDTAAA-UHFFFAOYSA-N 0.000 description 1
- CMVGKXLCWWUPQY-UHFFFAOYSA-N C[SiH](C)C.C1=CC=NC=C1 Chemical compound C[SiH](C)C.C1=CC=NC=C1 CMVGKXLCWWUPQY-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000282418 Hominidae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- UEIIHAFJUNVARH-UHFFFAOYSA-N N1(N=CC=C1)C1=NC=C(C=C1)C=1N=C2N(C=C(C=C2)I)C1.N1(N=CC=C1)C1=NC=C(C=C1)C=1N=C2N(C=C(C=C2)I)C1 Chemical compound N1(N=CC=C1)C1=NC=C(C=C1)C=1N=C2N(C=C(C=C2)I)C1.N1(N=CC=C1)C1=NC=C(C=C1)C=1N=C2N(C=C(C=C2)I)C1 UEIIHAFJUNVARH-UHFFFAOYSA-N 0.000 description 1
- HKUCEFWLAPIUCP-UHFFFAOYSA-N NC1=NC=C(C=C1)I.N1=CC=CC=C1 Chemical compound NC1=NC=C(C=C1)I.N1=CC=CC=C1 HKUCEFWLAPIUCP-UHFFFAOYSA-N 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000002013 dioxins Chemical class 0.000 description 1
- DWKKTAOVESMDCE-UHFFFAOYSA-N ditert-butyltin Chemical compound CC(C)(C)[Sn]C(C)(C)C DWKKTAOVESMDCE-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-BJUDXGSMSA-N fluorine-18 atom Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 description 1
- 150000005232 imidazopyridines Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- MGFYSGNNHQQTJW-UHFFFAOYSA-N iodonium Chemical compound [IH2+] MGFYSGNNHQQTJW-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- WXTYQJQQGUYCGM-UHFFFAOYSA-N n,n-dimethyl-4-(6-tributylstannylimidazo[1,2-a]pyridin-2-yl)aniline Chemical compound C=1N2C=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=1C1=CC=C(N(C)C)C=C1 WXTYQJQQGUYCGM-UHFFFAOYSA-N 0.000 description 1
- WSLPHQBLHUFGOM-UHFFFAOYSA-N n-(6-bromopyridin-3-yl)acetamide Chemical compound CC(=O)NC1=CC=C(Br)N=C1 WSLPHQBLHUFGOM-UHFFFAOYSA-N 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011140069 | 2011-06-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201300388A TW201300388A (zh) | 2013-01-01 |
| TWI554511B true TWI554511B (zh) | 2016-10-21 |
Family
ID=47422429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW101119585A TWI554511B (zh) | 2011-06-24 | 2012-05-31 | New amyloid affinity compounds (8) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9211350B2 (https=) |
| EP (1) | EP2725027B1 (https=) |
| JP (1) | JP5167436B2 (https=) |
| KR (1) | KR101854228B1 (https=) |
| CN (1) | CN103596950B (https=) |
| AU (1) | AU2012274639B2 (https=) |
| CA (1) | CA2839199C (https=) |
| ES (1) | ES2619830T3 (https=) |
| IN (1) | IN2014DN00185A (https=) |
| TW (1) | TWI554511B (https=) |
| WO (1) | WO2012176587A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107105667B (zh) * | 2014-08-29 | 2021-08-17 | Chdi基金会股份有限公司 | 用于成像亨廷顿蛋白的探针 |
| CN111372940A (zh) * | 2017-09-19 | 2020-07-03 | 阿尔伯塔大学理事会 | 生物还原活化的化合物、其前药、放射性药物、组合物及其在包括癌症在内的低氧疾病的多模式治疗控制中的应用 |
| JP6831802B2 (ja) * | 2018-01-12 | 2021-02-17 | 上海富吉医療器械有限公司Ｓｈａｎｇｈａｉ Ｃｈａｒｔｗｅｌｌ Ｍｅｄｉｃａｌ Ｉｎｓｔｒｕｍｅｎｔ Ｃｏ．， Ｌｔｄ． | 放射性核種標識化合物及びこれを含有するイメージング剤 |
| JPWO2022244680A1 (https=) * | 2021-05-18 | 2022-11-24 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007033080A2 (en) * | 2005-09-12 | 2007-03-22 | Emory University | Alzheimer's disease imaging agents |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU759945B2 (en) | 1998-08-20 | 2003-05-01 | Regents Of The University Of California, The | Methods for labeling beta-amyloid plaques and neurofibrillary tangles |
| RU2324686C2 (ru) | 2000-08-24 | 2008-05-20 | Юнивесити Оф Питсбэг | ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА |
| CA2444214A1 (en) | 2001-04-23 | 2002-10-31 | The Trustees Of The University Of Pennsylvania | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
| CN1299777C (zh) | 2001-08-27 | 2007-02-14 | 宾夕法尼亚州大学理事会 | 茋衍生物及其用于结合和成像淀粉样蛋白斑的用途 |
| WO2007063946A1 (ja) | 2005-11-30 | 2007-06-07 | Fujifilm Ri Pharma Co., Ltd. | アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬 |
| US8303935B2 (en) | 2006-05-19 | 2012-11-06 | Nihon Medi-Physics Co., Ltd. | Alkoxy substituted imidazo[1,2-a]pyridines having affinity for amyloid |
| WO2007148755A1 (ja) | 2006-06-21 | 2007-12-27 | Nihon Medi-Physics Co., Ltd. | 新規アミロイド親和性化合物 |
| CA2670436A1 (en) | 2006-11-30 | 2008-06-05 | Nihon Medi-Physics Co., Ltd. | Novel compound having affinity for amyloid |
| WO2008091195A1 (en) * | 2007-01-22 | 2008-07-31 | Astrazeneca Ab | Novel heteroaryl substituted imidazo [1,2 -a] pyridine derivatives |
| KR20100091965A (ko) | 2007-10-24 | 2010-08-19 | 니혼 메디피직스 가부시키가이샤 | 신규 아밀로이드 친화성 화합물 |
| AU2008314871A1 (en) | 2007-10-26 | 2009-04-30 | Nihon Medi-Physics Co., Ltd. | Novel compound having affinity for amyloid |
| KR20100101577A (ko) | 2007-10-30 | 2010-09-17 | 니혼 메디피직스 가부시키가이샤 | 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법 |
| WO2009057576A1 (ja) | 2007-10-30 | 2009-05-07 | Nihon Medi-Physics Co., Ltd. | 新規アミロイド親和性化合物の使用及び製造方法 |
| CA2704168A1 (en) | 2007-10-30 | 2009-05-07 | Nihon Medi-Physics Co., Ltd. | Use of novel compound having affinity for amyloid, and process for production of the same |
| WO2009155024A1 (en) * | 2008-05-30 | 2009-12-23 | Merck & Co., Inc. | Novel substituted indoles |
| EP2218464A1 (en) * | 2009-02-11 | 2010-08-18 | Technische Universität München | Compounds for non-invasive measurement of aggregates of amyloid peptides |
| WO2010128595A1 (ja) | 2009-05-07 | 2010-11-11 | 富士フイルムＲｉファーマ株式会社 | 放射性ヨウ素標識イミダゾピリジン誘導体の製造法 |
| US20120263646A1 (en) | 2009-10-15 | 2012-10-18 | Guerbet | Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
| AU2012259929B2 (en) * | 2011-05-20 | 2016-08-04 | Nihon Medi-Physics Co., Ltd. | Novel compound having affinity for amyloid |
-
2012
- 2012-05-29 CA CA2839199A patent/CA2839199C/en not_active Expired - Fee Related
- 2012-05-29 JP JP2012540219A patent/JP5167436B2/ja active Active
- 2012-05-29 CN CN201280027545.0A patent/CN103596950B/zh active Active
- 2012-05-29 EP EP12802179.7A patent/EP2725027B1/en active Active
- 2012-05-29 KR KR1020137032274A patent/KR101854228B1/ko not_active Expired - Fee Related
- 2012-05-29 US US14/128,903 patent/US9211350B2/en active Active
- 2012-05-29 ES ES12802179.7T patent/ES2619830T3/es active Active
- 2012-05-29 WO PCT/JP2012/063726 patent/WO2012176587A1/ja not_active Ceased
- 2012-05-29 AU AU2012274639A patent/AU2012274639B2/en not_active Ceased
- 2012-05-29 IN IN185DEN2014 patent/IN2014DN00185A/en unknown
- 2012-05-31 TW TW101119585A patent/TWI554511B/zh not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007033080A2 (en) * | 2005-09-12 | 2007-03-22 | Emory University | Alzheimer's disease imaging agents |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5167436B2 (ja) | 2013-03-21 |
| CA2839199C (en) | 2018-11-06 |
| US20140121377A1 (en) | 2014-05-01 |
| EP2725027A1 (en) | 2014-04-30 |
| KR20140040735A (ko) | 2014-04-03 |
| IN2014DN00185A (https=) | 2015-07-10 |
| EP2725027A4 (en) | 2015-02-25 |
| CN103596950B (zh) | 2017-12-19 |
| US9211350B2 (en) | 2015-12-15 |
| AU2012274639A1 (en) | 2014-02-06 |
| KR101854228B1 (ko) | 2018-05-03 |
| ES2619830T3 (es) | 2017-06-27 |
| AU2012274639B2 (en) | 2016-08-11 |
| JPWO2012176587A1 (ja) | 2015-02-23 |
| EP2725027B1 (en) | 2017-03-01 |
| CN103596950A (zh) | 2014-02-19 |
| WO2012176587A1 (ja) | 2012-12-27 |
| CA2839199A1 (en) | 2012-12-27 |
| TW201300388A (zh) | 2013-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI528977B (zh) | New amyloid affinity products | |
| JP5313158B2 (ja) | 新規アミロイド親和性化合物 | |
| JP5180838B2 (ja) | 新規アミロイド親和性化合物 | |
| JPWO2009054496A1 (ja) | 新規アミロイド親和性化合物 | |
| JPWO2009057578A1 (ja) | 新規アミロイド親和性化合物の使用及び製造方法 | |
| TWI554511B (zh) | New amyloid affinity compounds (8) | |
| JPWO2008059714A1 (ja) | 新規アミロイド親和性化合物 | |
| JPWO2009057577A1 (ja) | 新規アミロイド親和性化合物の使用及び製造方法 | |
| JPWO2009057575A1 (ja) | 新規アミロイド親和性化合物の使用及び製造方法 | |
| HK1193605A (en) | Novel compound with amyloid affinity | |
| HK1193605B (en) | Novel compound with amyloid affinity | |
| HK1193815B (en) | Compound having affinity for amyloid | |
| JP2009120591A (ja) | 新規アミロイド親和性化合物 | |
| JP2009120590A (ja) | 新規アミロイド親和性化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |